Literature DB >> 2884566

Visual improvement with SMS 201-995 in a patient with a thyrotropin-secreting pituitary adenoma.

P J Guillausseau, P Chanson, J Timsit, A Warnet, E Lajeunie, M Duet, J Lubetski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2884566     DOI： 10.1056/NEJM198707023170113

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  TSH-Secreting Pituitary Adenoma: Current Management and Review.

Authors:  M K Kole; J Goldman; J P Rock
Journal:  Skull Base Surg       Date:  1997

2.  Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide.

Authors:  P Iglesias; J J Díez
Journal:  J Endocrinol Invest       Date:  1998-12       Impact factor: 4.256

3.  Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma.

Authors:  N P Verhoeff; F J Bemelman; W M Wiersinga; E A van Royen
Journal:  Eur J Nucl Med       Date:  1993-06

4.  Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide.

Authors:  S M Orme; J T Lamb; M Nelson; P E Belchetz
Journal:  Postgrad Med J       Date:  1991-05       Impact factor: 2.401

Review 5.  Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours.

Authors:  P Chanson; J Timsit; A G Harris
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

Review 6.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.